uniQure Revenue and Competitors
Estimated Revenue & Valuation
- uniQure's estimated annual revenue is currently $500.4M per year.
- uniQure's estimated revenue per employee is $712,821
- uniQure's current valuation is $934M. (January 2022)
Employee Data
- uniQure has 702 Employees.
- uniQure grew their employee count by 5% last year.
uniQure's People
Name | Title | Email/Phone |
---|---|---|
1 | Executive Assistant to Chief Medical Officer and SVP, Regulatory Affairs | Reveal Email/Phone |
2 | Chief People and Culture Officer (Interim) | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | CEO | Reveal Email/Phone |
5 | Biosafety officer | Reveal Email/Phone |
6 | Executive Assistant To CEO and Chief Legal Officer | Reveal Email/Phone |
7 | VP Global Manufacturing Operations | Reveal Email/Phone |
8 | VP, New Product Planning (Global and US Commercialization Strategy) | Reveal Email/Phone |
9 | Head Commercial | Reveal Email/Phone |
10 | VP, Legal | Reveal Email/Phone |
uniQure Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7M | 45 | -34% | N/A | N/A |
#2 | $10.4M | 67 | -7% | N/A | N/A |
#3 | $10.2M | 66 | 6% | N/A | N/A |
#4 | $6.7M | 43 | -2% | N/A | N/A |
#5 | $23.3M | 150 | -18% | N/A | N/A |
#6 | $35.8M | 231 | 9% | N/A | N/A |
#7 | $11.2M | 72 | -18% | N/A | N/A |
#8 | $15.2M | 98 | 3% | N/A | N/A |
#9 | $1.7M | 11 | -52% | N/A | N/A |
#10 | $10.1M | 65 | 7% | N/A | N/A |
What Is uniQure?
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
keywords:N/AN/A
Total Funding
702
Number of Employees
$500.4M
Revenue (est)
5%
Employee Growth %
$934M
Valuation
N/A
Accelerator
uniQure News
On behalf of the Board of Directors of uniQure N.V. (the Company), I invite you to attend our 2022 Annual General Meeting of Shareholders...
uniQure N.V. (NASDAQ:QURE) is a great speculative biotech to look into. The reason why I state this is because its main clinical program,...
The multi-year clinical development was led by uniQure (NASDAQ:QURE) and sponsorship of the trials in the U.S. has transitioned to CSL Behring...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $128.3M | 705 | 45% | N/A |
#2 | $3.5M | 714 | 33% | N/A |
#3 | $272.2M | 720 | 7% | N/A |
#4 | $206.9M | 721 | 6% | N/A |
#5 | $212.3M | 722 | 10% | N/A |